What the Peer-Reviewed Record Establishes
The primary research record in Angiogenic Biomarkers & sFlt-1/PlGF Diagnostic Ratios is stratified by study design so that meta-analyses and replicated randomised controlled trials (T1–T2) carry greater epistemic weight than observational cohorts (T3–T4) or preclinical laboratory work (T5). Leading graded findings establish the core empirical baseline: [T1] Patients underwent delivery to terminate preeclampsia within 48 h of admission. [13] [T3] Quantification of the soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) ratio has shown a diagnostic value in the second and third trimesters of pregnancy, in particular in ruling out preeclampsia within one week. [14]
Further clinical and mechanistic stratification across the literature demonstrates: [T3] In patients with suspected preeclampsia, the diagnostic accuracy of the sFlt-1/PlGF ratio (false positive rate of 26% for a detection rate of 80%) was higher than that of sFlt-1 and PlGF in isolation. [8] [T3] ObjectiveTo assess the diagnostic performance of angiogenic biomarkers in determining need for delivery in seven days in women with late preterm preeclampsia.Study designIn a prospective observational cohort study in 36 maternity units across England and Wales [12]
Comparative Evaluation of Levers & Theoretical Models
Within Reproductive Medicine & Human Fertility → Advanced Maternal Age & Pregnancy After 40, mechanistic and clinical evaluation in Angiogenic Biomarkers & sFlt-1/PlGF Diagnostic Ratios focuses on predictive value and clinical rule-out/rule-in performance of soluble fms-like tyrosine kinase-1 and placental growth factor across gestation. Primary publications in the current corpus span Cureus, Africa Clinical Research Network (ACRN), Obstetric medicine, Discoveries (Craiova, Romania).
Evolution of the Field, Open Debates & Active Trials
Chronologically, the field evolved through key inflection points: in 2008, Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. (ObjectiveTo evaluate the ability of endoglin, placental growth factor (PlGF) and the soluble form of vascular endothelial growth factor receptor (sFlt-1) measurements in gestational weeks 24-28 were used to predict pre-eclampsia.DesignObservational, prospectiv); in 2024, A Second Trimester Prediction Algorithm for Early-Onset Hypertensive Disorders of Pregnancy Occurrence and S… (Hypertensive disorders of pregnancy (HDPs) represent a significant source of severe maternal and fetal morbidity); in 2026, PROTECT-Africa: Biomarker Validation for Preeclampsia Triage (Preeclampsia is a serious high blood pressure condition that can develop during pregnancy).
Open Questions & Priorities for the Next Research Sweep
Methodological priorities and open empirical questions queued for the next research sweep across Angiogenic Biomarkers & sFlt-1/PlGF Diagnostic Ratios focus on resolving subgroup effect sizes, causal mechanisms, and long-term outcomes:
- Large-scale multicentre randomised controlled trials with standardised live-birth and long-term offspring follow-up in sFlt-1/PlGF Ratio Diagnostic and Predictive Accuracy.
- Age- and subgroup-stratified biomarker validation across diverse human populations.